{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T18:35:54Z","timestamp":1763663754631,"version":"3.44.0"},"reference-count":18,"publisher":"BMJ","issue":"4","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Frontline Gastroenterol"],"accepted":{"date-parts":[[2018,3,20]]},"published-print":{"date-parts":[[2018,10]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Interest in the use of faecal microbiota transplantation (FMT) in inflammatory bowel disease (IBD) has increased following outcomes in patients with <jats:italic>Clostridioides difficile<\/jats:italic> infection (CDI). While research exploring clinician awareness and attitude towards the use of FMT in CDI has been carried out, data for IBD are currently lacking.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To assess the perceptions of gastroenterologists and current practice relating to FMT as a treatment for IBD in the UK.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design<\/jats:title>\n                  <jats:p>A web-based survey (Snap Survey software) was distributed through the British Society of Gastroenterology (BSG) and British Society of Paediatric Gastroenterology, Hepatology and Nutrition e-newsletters, and at the BSG Conference in June 2017.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>61 respondents completed the survey including presubspecialty trainees, gastroenterology specialists, associate specialists and consultants. Most (95%; n=58) respondents stated that they had heard of FMT being used as a treatment for IBD prior to participating in the survey. Based on current evidence, 34% (n=21) of respondents would consider using FMT in patients with IBD, 26% (n=16) would not and 39% (n=24) were undecided. When asked to rank routes of delivery in terms of preference, nasogastric tube was the least preferred route (39%; n=24) and oral capsule was the most preferred route (34%; n=21).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>A clear majority of UK gastroenterologists recognise FMT as a potential treatment for IBD; however, uptake is limited. A proportion of clinicians would consider FMT in IBD and the majority would consider entering patients into clinical trials. Future work should explore the utility and efficacy of oral FMT capsules in IBD.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/flgastro-2017-100936","type":"journal-article","created":{"date-parts":[[2018,4,29]],"date-time":"2018-04-29T12:25:36Z","timestamp":1525004736000},"page":"250-255","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":9,"title":["Faecal microbiota transplantation as a treatment for inflammatory bowel disease: a national survey of adult and paediatric gastroenterologists in the UK"],"prefix":"10.1136","volume":"9","author":[{"given":"James Roger","family":"Mcilroy","sequence":"first","affiliation":[{"name":"School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Aberdeen, UK"},{"name":"EnteroBiotix Limited, Aberdeen, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niharika","family":"Nalagatla","sequence":"additional","affiliation":[{"name":"School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Aberdeen, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Hansen","sequence":"additional","affiliation":[{"name":"Royal Hospital for Children, Glasgow, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ailsa","family":"Hart","sequence":"additional","affiliation":[{"name":"IBD Unit, St Mark\u2019s Hospital, Harrow, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgina Louise","family":"Hold","sequence":"additional","affiliation":[{"name":"School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Aberdeen, UK"},{"name":"Department of Medicine, University of New South Wales, Sydney, New South Wales, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2018,4,29]]},"reference":[{"key":"2025090708205921000_9.4.250.1","unstructured":"Nice N . Faecal microbiota transplant for recurrent Clostridium difficile infection: NICE Interventional Procedure Guidance. 2014:485."},{"key":"2025090708205921000_9.4.250.2","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1093\/ofid\/ofw172.1776","article-title":"Impact of Amoxicillin\/clavulanate and autologous fecal microbiota transplantation (fmt) on the fecal microbiome and resistome","volume":"3","author":"Bulrow","year":"2016","journal-title":"Open Forum Infectious Diseases"},{"key":"2025090708205921000_9.4.250.3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/apt.14384","article-title":"Review article: the gut microbiome in inflammatory bowel disease-avenues for microbial management","volume":"47","author":"McIlroy","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"2025090708205921000_9.4.250.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.anaerobe.2016.06.008"},{"key":"2025090708205921000_9.4.250.5","doi-asserted-by":"publisher","DOI":"10.1111\/apt.14201"},{"key":"2025090708205921000_9.4.250.6","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.03.045"},{"key":"2025090708205921000_9.4.250.7","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.04.001"},{"key":"2025090708205921000_9.4.250.8","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1016\/S0140-6736(17)30182-4","article-title":"Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial","volume":"389","author":"Paramsothy","year":"2017","journal-title":"The Lancet"},{"key":"2025090708205921000_9.4.250.9","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1093\/ecco-jcc\/jjx002.035","article-title":"OP036 Short duration, low intensity pooled faecal microbiota transplantation induces remission in patients with mild-moderately active ulcerative colitis: a randomised controlled trial","volume":"11","author":"Costello","year":"2017","journal-title":"Journal of Crohn\u2019s and Colitis"},{"key":"2025090708205921000_9.4.250.10","doi-asserted-by":"publisher","DOI":"10.1111\/apt.14173"},{"key":"2025090708205921000_9.4.250.11","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1093\/ecco-jcc\/jjx063","article-title":"Faecal microbiota transplantation for inflammatory bowel disease: a systematic review and meta-analysis","volume":"11","author":"Paramsothy","year":"2017","journal-title":"J Crohns Colitis"},{"key":"2025090708205921000_9.4.250.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2015.01.020"},{"key":"2025090708205921000_9.4.250.13","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.jhin.2016.10.023","article-title":"National survey of practice of faecal microbiota transplantation for Clostridium difficile infection in the UK","volume":"95","author":"Quraishi","year":"2017","journal-title":"J Hosp Infect"},{"key":"2025090708205921000_9.4.250.14","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0000000000000405"},{"key":"2025090708205921000_9.4.250.15","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0b013e318281f520"},{"key":"2025090708205921000_9.4.250.16","unstructured":"OpenBiome. Home. 2017. www.openbiome.org (accessed 23 Aug 2017)."},{"key":"2025090708205921000_9.4.250.17","unstructured":"EnteroBiotix. Modulating the human microbiome to address important unmet clinical needs. 2017. http:\/\/www.enterobiotix.com (accessed 23 Aug 2017)."},{"key":"2025090708205921000_9.4.250.18","doi-asserted-by":"publisher","DOI":"10.7326\/M16-0271"}],"container-title":["Frontline Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/flgastro-2017-100936","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T15:21:11Z","timestamp":1757258471000},"score":1,"resource":{"primary":{"URL":"https:\/\/fg.bmj.com\/lookup\/doi\/10.1136\/flgastro-2017-100936"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,29]]},"references-count":18,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2018,9,7]]},"published-print":{"date-parts":[[2018,10]]}},"alternative-id":["10.1136\/flgastro-2017-100936"],"URL":"https:\/\/doi.org\/10.1136\/flgastro-2017-100936","relation":{},"ISSN":["2041-4137","2041-4145"],"issn-type":[{"type":"print","value":"2041-4137"},{"type":"electronic","value":"2041-4145"}],"subject":[],"published":{"date-parts":[[2018,4,29]]}}}